{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:53:45Z","timestamp":1788350025838,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005039","name":"Leiden University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Osteoid osteoma and osteoblastoma are bone-forming tumors shown to harbor\n                    <jats:italic>FOS<\/jats:italic>\n                    (87%) and\n                    <jats:italic>FOSB<\/jats:italic>\n                    (3%) rearrangements. The aim was to evaluate the immunohistochemical expression of FOS and FOSB in these tumors in comparison to other bone tumors, to evaluate the influence of decalcification, and to correlate immunohistochemical findings with the underlying genetic alteration using fluorescence in situ hybridization (FISH). Immunohistochemistry using whole sections was performed on osteoid osteoma (\n                    <jats:italic>n<\/jats:italic>\n                    =23), osteoblastoma (\n                    <jats:italic>n<\/jats:italic>\n                    =22), osteoblastoma-like osteosarcoma (\n                    <jats:italic>n<\/jats:italic>\n                    =3), reactive (\n                    <jats:italic>n<\/jats:italic>\n                    =3), and proliferative (\n                    <jats:italic>n<\/jats:italic>\n                    =11) bone lesions. Immunoreactivity in giant cell tumor of bone (\n                    <jats:italic>n<\/jats:italic>\n                    =74), aneurysmal bone cyst (\n                    <jats:italic>n<\/jats:italic>\n                    =6), chondromyxoid fibroma (\n                    <jats:italic>n<\/jats:italic>\n                    =20), osteosarcoma (\n                    <jats:italic>n<\/jats:italic>\n                    =85), chondroblastoma (\n                    <jats:italic>n<\/jats:italic>\n                    =17), and clear cell chondrosarcoma (\n                    <jats:italic>n<\/jats:italic>\n                    =20) was assessed using tissue micro arrays. Strong nuclear expression of FOS in &gt; 50% of the tumor cells was observed in all osteoid osteomas (22\/22), in 57% of osteoblastomas (12\/21) and in 3\/197 control cases. FOS immunoreactivity disappeared after &gt; 3 days decalcification.\n                    <jats:italic>FOS<\/jats:italic>\n                    rearrangements were present in 94% of osteoid osteomas and osteoblastomas, with a concordance of 86% between FISH and immunohistochemistry. Two osteoblastomas (5%) were positive for FOSB, as opposed to 8\/177 control cases. Additional FISH revealed no\n                    <jats:italic>FOSB<\/jats:italic>\n                    rearrangements in these cases. To conclude, in short decalcified biopsies, FOS immunohistochemistry can be used to diagnose osteoid osteoma and osteoblastoma, as overexpression is seen in the majority, being rare in their mimics. FOS immunohistochemistry should not be used after long decalcification. Moreover, low level of focal expression found in other lesions and tissues might cause diagnostic problems, in which case FISH could be employed.\n                  <\/jats:p>","DOI":"10.1007\/s00428-019-02684-9","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T05:02:37Z","timestamp":1574658157000},"page":"455-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma"],"prefix":"10.1007","volume":"476","author":[{"given":"Suk Wai","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen H. G.","family":"Cleven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman M.","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge H.","family":"Briaire-de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoly","family":"Szuhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-0481","authenticated-orcid":false,"given":"Judith V. M. G.","family":"Bov\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"2684_CR1","first-page":"1007","volume":"46","author":"HL Jaffe","year":"1953","unstructured":"Jaffe HL (1953) Osteoid-osteoma. Proc R Soc Med 46:1007\u20131012","journal-title":"Proc R Soc Med"},{"key":"2684_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archsurg.1935.01180170034003","volume":"31","author":"HL Jaffe","year":"1935","unstructured":"Jaffe HL (1935) \"Osteoid-osteoma\": a benign osteoblastic tumor composed of osteoid and atypical bone. Arch Surg 31:709\u2013728. https:\/\/doi.org\/10.1001\/archsurg.1935.01180170034003","journal-title":"Arch Surg"},{"key":"2684_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3109\/17453677008991514","volume":"41","author":"F Schajowicz","year":"1970","unstructured":"Schajowicz F, Lemos C (1970) Osteoid osteoma and osteoblastoma. Closely related entities of osteoblastic derivation. Acta Orthop Scand 41:272\u2013291","journal-title":"Acta Orthop Scand"},{"key":"2684_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jmoldx.2018.11.002","volume":"21","author":"SW Lam","year":"2019","unstructured":"Lam SW, van Jzendoorn DGP, Cleton-Jansen AM, Szuhai K, Bovee JVMG (2019) Molecular pathology of bone tumors. J Mol Diagn 21:171\u2013182. https:\/\/doi.org\/10.1016\/j.jmoldx.2018.11.002","journal-title":"J Mol Diagn"},{"key":"2684_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/gcc.22699","volume":"58","author":"D Baumhoer","year":"2019","unstructured":"Baumhoer D, Amary F, Flanagan AM (2019) An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosom Cancer 58:88\u201399. https:\/\/doi.org\/10.1002\/gcc.22699","journal-title":"Genes Chromosom Cancer"},{"key":"2684_CR6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41467-018-04530-z","volume":"9","author":"MW Fittall","year":"2018","unstructured":"Fittall MW, Mifsud W, Pillay N, Ye H, Strobl AC, Verfaillie A, Demeulemeester J, Zhang L, Berisha F, Tarabichi M, Young MD, Miranda E, Tarpey PS, Tirabosco R, Amary F, Grigoriadis AE, Stratton MR, Van Loo P, Antonescu CR, Campbell PJ, Flanagan AM, Behjati S (2018) Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nat Commun 9:2150. https:\/\/doi.org\/10.1038\/s41467-018-04530-z","journal-title":"Nat Commun"},{"key":"2684_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.0105-2896.2005.00332.x","volume":"208","author":"EF Wagner","year":"2005","unstructured":"Wagner EF, Eferl R (2005) Fos\/AP-1 proteins in bone and the immune system. Immunol Rev 208:126\u2013140. https:\/\/doi.org\/10.1111\/j.0105-2896.2005.00332.x","journal-title":"Immunol Rev"},{"key":"2684_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/gcc.22269","volume":"54","author":"DGP van IJzendoorn","year":"2015","unstructured":"van IJzendoorn DGP, de Jong D, Romagosa C, Picci P, Benassi MS, Gambarotti M, Daugaard S, van de Sande M, Szuhai K, Bovee JV (2015) Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. Genes Chromosom Cancer 54:565\u2013574. https:\/\/doi.org\/10.1002\/gcc.22269","journal-title":"Genes Chromosom Cancer"},{"key":"2684_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/pas.0000000000000469","volume":"39","author":"SC Huang","year":"2015","unstructured":"Huang SC, Zhang L, Sung YS, Chen CL, Krausz T, Dickson BC, Kao YC, Agaram NP, Fletcher CD, Antonescu CR (2015) Frequent FOS gene rearrangements in epithelioid hemangioma: a molecular study of 58 cases with morphologic reappraisal. Am J Surg Pathol 39:1313\u20131321. https:\/\/doi.org\/10.1097\/pas.0000000000000469","journal-title":"Am J Surg Pathol"},{"key":"2684_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/path.4322","volume":"232","author":"C Walther","year":"2014","unstructured":"Walther C, Tayebwa J, Lilljebjorn H, Magnusson L, Nilsson J, von Steyern FV, Ora I, Domanski HA, Fioretos T, Nord KH, Fletcher CD, Mertens F (2014) A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. J Pathol 232:534\u2013540. https:\/\/doi.org\/10.1002\/path.4322","journal-title":"J Pathol"},{"key":"2684_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/gcc.22206","volume":"53","author":"CR Antonescu","year":"2014","unstructured":"Antonescu CR, Chen HW, Zhang L, Sung YS, Panicek D, Agaram NP, Dickson BC, Krausz T, Fletcher CD (2014) ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features. Genes Chromosom Cancer 53:951\u2013959. https:\/\/doi.org\/10.1002\/gcc.22206","journal-title":"Genes Chromosom Cancer"},{"key":"2684_CR12","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1097\/pas.0000000000000512","volume":"39","author":"AH Cleven","year":"2015","unstructured":"Cleven AH, Hocker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovee JVMG (2015) Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol 39:1576\u20131583. https:\/\/doi.org\/10.1097\/pas.0000000000000512","journal-title":"Am J Surg Pathol"},{"key":"2684_CR13","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1158\/1078-0432.ccr-10-2047","volume":"17","author":"EP Buddingh","year":"2011","unstructured":"Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton-Jansen AM (2011) Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 17:2110\u20132119. https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-2047","journal-title":"Clin Cancer Res"},{"key":"2684_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2045-3329-1-5","volume":"1","author":"D Meijer","year":"2011","unstructured":"Meijer D, Gelderblom H, Karperien M, Cleton-Jansen AM, Hogendoorn PC, Bovee JV (2011) Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. Clin Sarcoma Res 1:5. https:\/\/doi.org\/10.1186\/2045-3329-1-5","journal-title":"Clin Sarcoma Res"},{"key":"2684_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00262-016-1925-3","volume":"66","author":"YT Sundara","year":"2017","unstructured":"Sundara YT, Kostine M, Cleven AH, Bovee JV, Schilham MW, Cleton-Jansen AM (2017) Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother 66:119\u2013128. https:\/\/doi.org\/10.1007\/s00262-016-1925-3","journal-title":"Cancer Immunol Immunother"},{"key":"2684_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/pas.0000000000000795","volume":"41","author":"YP Hung","year":"2017","unstructured":"Hung YP, Fletcher CD, Hornick JL (2017) FOSB is a useful diagnostic marker for pseudomyogenic hemangioendothelioma. Am J Surg Pathol 41:596\u2013606. https:\/\/doi.org\/10.1097\/pas.0000000000000795","journal-title":"Am J Surg Pathol"},{"key":"2684_CR17","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1158\/1078-0432.ccr-17-3512","volume":"24","author":"DGP van IJzendoorn","year":"2018","unstructured":"van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens F, van Leenders G, Szuhai K, Bovee J (2018) Telatinib is an effective targeted therapy for pseudomyogenic hemangioendothelioma. Clin Cancer Res 24:2678\u20132687. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-3512","journal-title":"Clin Cancer Res"},{"key":"2684_CR18","doi-asserted-by":"publisher","first-page":"8.5.1","DOI":"10.1002\/0471142956.cy0805s05","volume":"5","author":"AHN Hopman","year":"1998","unstructured":"Hopman AHN, Ramaekers FCS (1998) Processing and staining of cell and tissue material for interphase cytogenetics. Curr Protocol Cytom 5:8.5.1\u20138.5.22","journal-title":"Curr Protocol Cytom"},{"key":"2684_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s004280050199","volume":"432","author":"A Franchi","year":"1998","unstructured":"Franchi A, Calzolari A, Zampi G (1998) Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch 432:515\u2013519","journal-title":"Virchows Arch"},{"key":"2684_CR20","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1136\/jcp.2007.047720","volume":"61","author":"G Bussolati","year":"2008","unstructured":"Bussolati G, Leonardo E (2008) Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 61:1184\u20131192. https:\/\/doi.org\/10.1136\/jcp.2007.047720","journal-title":"J Clin Pathol"},{"key":"2684_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1083\/jcb.201002111","volume":"190","author":"A Bozec","year":"2010","unstructured":"Bozec A, Bakiri L, Jimenez M, Schinke T, Amling M, Wagner EF (2010) Fra-2\/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. J Cell Biol 190:1093\u20131106. https:\/\/doi.org\/10.1083\/jcb.201002111","journal-title":"J Cell Biol"},{"key":"2684_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1083\/jcb.122.3.685","volume":"122","author":"AE Grigoriadis","year":"1993","unstructured":"Grigoriadis AE, Schellander K, Wang ZQ, Wagner EF (1993) Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 122:685\u2013701","journal-title":"J Cell Biol"},{"key":"2684_CR23","doi-asserted-by":"publisher","first-page":"21282","DOI":"10.1074\/jbc.C117.815845","volume":"292","author":"DGP van IJzendoorn","year":"2017","unstructured":"van IJzendoorn DGP, Forghany Z, Liebelt F, Vertegaal AC, Jochemsen AG, Bovee J, Szuhai K, Baker DA (2017) Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis. J Biol Chem 292:21282\u201321290. https:\/\/doi.org\/10.1074\/jbc.C117.815845","journal-title":"J Biol Chem"},{"key":"2684_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.path.2017.04.003","volume":"10","author":"DGP van IJzendoorn","year":"2017","unstructured":"van IJzendoorn DGP, JVMG B (2017) Vascular tumors of bone: the evolvement of a classification based on molecular developments. Surg Pathol Clin 10:621\u2013635. https:\/\/doi.org\/10.1016\/j.path.2017.04.003","journal-title":"Surg Pathol Clin"},{"key":"2684_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12105-010-0234-y","volume":"5","author":"C Harrington","year":"2011","unstructured":"Harrington C, Accurso BT, Kalmar JR, Iwenofu OH, Agrawal A, Allen CM, Leon ME (2011) Aggressive osteoblastoma of the maxilla: a case report and review of the literature. Head Neck Pathol 5:165\u2013170. https:\/\/doi.org\/10.1007\/s12105-010-0234-y","journal-title":"Head Neck Pathol"},{"key":"2684_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/1097-0142(19850115)55:2<416::AID-CNCR2820550221>3.0.CO;2-5","volume":"55","author":"F Bertoni","year":"1985","unstructured":"Bertoni F, Unni KK, McLeod RA, Dahlin DC (1985) Osteosarcoma resembling osteoblastoma. Cancer. 55:416\u2013426","journal-title":"Cancer."}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-019-02684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-019-02684-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-019-02684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T20:49:43Z","timestamp":1606164583000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-019-02684-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["2684"],"URL":"https:\/\/doi.org\/10.1007\/s00428-019-02684-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"1 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All samples were handled according to the ethical guidelines described in \u201cCode for Proper Secondary Use of Human Tissue in the Netherlands\u201d in a coded (pseudonymized) manner, as approved by the Leiden University Medical Center ethical board (B17.036 and B19.007).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}